References
- Fogelman I , Smith L , Mazess R , et al . Absorption of ral diphosphonate in normal subjects. Clin Endocrinol 1986;24:57–62.
- Gertz BJ , Holland SD , Kline WF , et al . Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995;58:288–98.
- Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75–85.
- Gertz BJ , Holland SD , Kline WF , et al . Clinical pharmacol-ogy of alendronate sodium. Osteoporos Int 1993;3:513–6.
- Recker RR , Saville RD . Intestinal absorption of disodium ethane-1-hydroxyl-1 1-diphosphonate (disodium etidronate) using a deconvolution technique. Toxicol Appl Pharmacol 1973;24:580–9.
- Osterman T , Juhakoski A , Lauren L , et al . Effect of iron on the absorption and distribution of clodronate after oral administration in rats. Pharmacol Toxicol 1994;74:267–70.
- Patel R , Blake G , Rymer J , Fogelman I . Long-term precision of DXA scanning assessed over 7 years in 40 postmenopausal women. Osteoporos Int 1994 (in press).
- van Staa TP. Postmarketing experience with intermittent cyclical etidronate therapy. Rev Contemp Pharmacother. 1998;9:277–86.
- van Staa TP , Abenhaim L , Cooper C. Upper gastrointestinal adverse events and cyclical etidronate. Am J Med 1997;103:462–7.
- Dunn CJ , Fitton A , Sorkin EM. Etidronic acid: a review of its pharmacological properties and therapeutic efficacy in resorp-five bone diseases. Drugs Aging 1994;5:446–74.